TARRYTOWN, N.Y., April 17, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and its collaborator Bayer today announced that aflibercept 8 mg and EYLEA® (aflibercept) Injection ...
TARRYTOWN, N.Y., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced new analyses of EYLEA HD® (aflibercept) Injection 8 mg and EYLEA® (aflibercept) ...
Diabetic retinopathy in patients with DME is the fourth approved indication for EYLEA in the U.S. Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug ...
September 21, 2012 — The US Food and Drug Administration (FDA) has approved aflibercept injection (Eylea, Regeneron Pharmaceuticals) for treating macular edema following central retinal vein occlusion ...
Credit: Regeneron. Eylea HD is supplied as a sterile, aqueous solution for intravitreal injection in a single-dose vial containing 8mg of aflibercept. The Food and Drug Administration (FDA) has ...
Please provide your email address to receive an email when new articles are posted on . Investigators retrospectively analyzed visual and anatomic outcomes of patients who were attempted to be weaned ...
What is behind the bilateral eye pain and failing vision affecting a 96-year-old woman with neovascular age-related macular degeneration (nAMD)? That's what ophthalmologists needed to determine when ...
Roche is hyping up the early financials coming in for its eye disease therapy Vabysmo as the Swiss major looks to take on the might of Regeneron and Bayer’s major blockbuster, Eylea. Despite only ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results